RecruitingPhase 2NCT03826693

Efficacy of Nitrous Oxide in OCD: Pilot Study


Sponsor

Stanford University

Enrollment

45 participants

Start Date

Apr 17, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This pilot (small, early-stage) trial is studying whether nitrous oxide (commonly known as "laughing gas," used safely in medicine and dentistry for decades) given in controlled doses can reduce the symptoms of obsessive-compulsive disorder (OCD) — a condition involving repeated unwanted thoughts and compulsive behaviors. **You may be eligible if...** - You are between 18 and 65 years old - You have a primary diagnosis of OCD - Your OCD symptoms are severe enough to qualify - You are able to go without OCD treatment for a short period during the study - You are capable of giving informed consent **You may NOT be eligible if...** - You have a psychiatric or medical condition that would make it unsafe to receive nitrous oxide - You are pregnant or nursing - You are taking medications that could have dangerous interactions with nitrous oxide Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNitrous Oxide

OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.

DRUGNitrogen

OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.


Locations(1)

Stanford University

Stanford, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03826693


Related Trials